导航神经退行:挑战,病理生理学,生物标志物,以及基于纳米晶的纳米治疗的承诺
Gagandeep Kaur1, Jay Prakash Dewangan1, Anuradha Kumari1
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli (NIPER-R), Lucknow, UP, India.
Journal of microencapsulation
|May 26, 2025
概括
纳米晶技术通过增强溶解性和大脑透性来改善神经退行性疾病的药物输送. 这种方法为克服血脑屏障等挑战提供了一个有希望的解决方案.
科学领域:
- 制药科学 制药科学
- 纳米技术 纳米技术
- 神经科学是一个神经科学.
背景情况:
- 许多药物面临着溶解度低和选择性差的挑战,阻碍了有效的药物输送,特别是跨越血脑屏障 (BBB) 和血脑脊液 (CSF) 屏障.
- 药物溶解性差,目标部位度低,并通过排泄输送器快速清除,显著限制神经退行性疾病 (NDD) 的治疗选择.
研究的目的:
- 探索纳米晶 (NC) 技术的潜力,作为一种解决方案,用于增强神经退行性疾病的药物输送到大脑.
- 在NDDs的背景下,审查与NCs相关的合成方法,优势和挑战.
主要方法:
- 纳米晶体 (NC) 技术涉及生产微米以下的,具有高药物有效载荷的无载体颗粒,通过药剂稳定,以提高合体稳定性和保质期.
- 通过使用自上而下,自下而上和组合方法合成NC,使用像NANOEDGE®和SmartCrystals®这样的专利技术.
主要成果:
- 增加NC的表面积显著提高了疏水药物的可溶性,生物可用性和脑透性.
- 在神经退行性疾病中,NC技术为治疗和诊断应用提供了一个有前途的途径.
结论:
- 纳米晶技术提供了一种可行的策略,可以克服治疗神经退行性疾病的主要药物输送障碍.
- 需要进一步的研究来解决诸如热不稳定性,可扩展性和广泛临床应用的长期安全性等挑战.
相关概念视频
Alzheimer's Disease: Overview
689
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
689
Parkinson's Disease: Overview
726
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
726
Alzheimer's Disease: Treatment
266
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
266
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182


